Covista Inc.
In the published model solve dated 2026-Q2, anchored at $128.09, Covista Inc. (CVSA) is priced for -4.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Essentially all revenue is tuition, split across three healthcare-focused schools: Chamberlain at $197.0 million of March-quarter revenue, Walden at $186.6 million, and the medical and veterinary schools at $103.5 million. • The dominant risk is federal rather than commercial, and the 10-K says so directly: ⟦"Our ability to comply with several ED regulations is not entirely within our control"⟧, and a programme failing the government's outcomes test twice in three years loses access to federa
Is CVSA overvalued? See what's priced in →
341 institutional managers reported holding CVSA in 13F filings for the quarter ended 2026-03-31. 38 opened new positions that quarter. Held by BlackRock, Vanguard Group, FMR (Fidelity), among others. On the short side, 1.6M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (6.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CVSA has cut its share count 31% over the past five years, spending $962.21M on repurchases. It pays no dividend. Cash returned over the past three years: $714.96M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CVSA over the trailing three years: 2025: 3 buys totaling $229k; 2026: 4 buys totaling $3.75M. 23 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CVSA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-11 | -1.1% | +0.7% |
| 2023-10-27 | +12.4% | +18.1% |
| 2024-01-31 | +5.2% | +1.8% |
| 2024-05-03 | +18.9% | +13.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CVSA's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-07-28 (items 5.02, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-04-09 (items 7.01, 9.01); 2026-03-03 (items 1.01, 1.02, 2.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.